Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

BMS Pays CytomX $200M Upfront to Expand Probody Therapeutics Partnership

Bristol-Myers Squibb (BMS) is paying CytomX Therapeutics $200 million upfront to add up to eight new candidates to their ...

Forward this item to a colleague:

(Separate multiple addresses by commas)